Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Graeme Woodworth, MD
University of Maryland
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Maryland
Baltimore, Maryland, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- University of Virginia
Charlottesville, Virginia, United States
- West Virginia University
Morgantown, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Mar 2019
- Primary completion
- 31 Dec 2023
- Completion
- 31 Dec 2023
- Last update posted
- 20 Mar 2026
- Registered enrollment
- 20
- Registry id
- NCT03551249
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.